Filing summary
Entity and period: The supplied filing is ARCA biopharma, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015—not a filing for Oruka Therapeutics, Inc. The company focused on developing genetically targeted cardiovascular therapies, principally Gencaro.
Financial performance and position
| Metric | Q2 2015 / June 30, 2015 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None to date | None to date |
| Research and development expense | $1.747 million for Q2; $3.454 million for first half | $1.400 million and $2.708 million, respectively, in 2014 |
| General and administrative expense | $0.972 million for Q2; $2.009 million for first half | $1.006 million and $2.088 million, respectively, in 2014 |
| Net loss | $2.719 million for Q2; $5.463 million for first half | $2.405 million and $4.794 million, respectively, in 2014 |
| Operating cash flow | Cash used: $5.512 million in first half 2015 versus $5.450 million in first half 2014 | |
| Cash and cash equivalents | $44.086 million | $15.354 million at December 31, 2014 |
| Total assets / liabilities | $45.115 million / $1.357 million | $16.132 million / $1.391 million at December 31, 2014 |
| Stockholders’ equity | $43.758 million | $14.741 million at December 31, 2014 |
Margins are not meaningful because the company had no revenue. First-half financing cash flow was $34.251 million, primarily from a June private placement; investing cash use was $7,000. The filing reports minimal interest expense and vendor-financing repayments, but no material conventional debt balance is apparent in the presented balance sheet.
Changes and financing
- Q2 R&D expense rose about $0.3 million year over year, mainly from increased GENETIC-AF trial activity; first-half R&D rose about $0.7 million. Management expected R&D and G&A spending in 2015 to exceed 2014 levels.
- On June 16, ARCA issued 42.0 million shares and warrants for an aggregate of approximately $34 million net proceeds. The warrants cover up to 16.8 million additional shares, become exercisable in December 2015, and have a $0.8716 exercise price. Shares outstanding increased from 21.2 million at year-end 2014 to 63.2 million at June 30, 2015.
- Accumulated deficit increased to $90.1 million. Loss per share was $0.10 for Q2 and $0.22 for the first half, compared with $0.11 and $0.24 in 2014.
Outlook, risks and notable matters
- GENETIC-AF is an adaptive Phase 2B/3 trial of Gencaro versus metoprolol in genetically selected heart-failure patients with atrial fibrillation. After enrollment and follow-up of approximately 200 Phase 2B patients, the DSMB is to assess whether the trial should proceed to a planned additional 420-patient Phase 3 portion.
- Enrollment had been slower than originally projected. Protocol amendments were intended to broaden eligibility and simplify procedures. Management projected Phase 2B enrollment completion by year-end 2016 and the DSMB interim analysis in the first half of 2017, while cautioning that the effect of the changes was uncertain.
- The FDA granted Gencaro Fast Track designation in April 2015. This is not approval and does not ensure a successful trial or expedited approval.
- Management said available cash was expected to fund operations, at its projected cost structure, through at least the end of 2017. However, the filing states that substantial doubt exists about the company’s ability to continue as a going concern because development costs and timelines are uncertain and significant additional capital is needed, particularly if Phase 3 proceeds. Failure to raise funds or complete a strategic transaction could require curtailing development or operations.
- Potential future dilution is significant: the June financing issued substantial equity and warrants, and the filing identifies constraints on further fundraising. The Gencaro license also includes an $8 million milestone upon U.S. approval, potential additional regulatory milestones, and royalties on product revenue.
- Nasdaq notified ARCA in February 2015 of a potential delisting over the minimum bid price; it reported regaining compliance on July 15, 2015. The filing reports no legal proceedings and says disclosure controls were effective at a reasonable level of assurance.
Key facts for investors to verify
- Confirm the issuer: this document is ARCA biopharma’s 2015 Q2 filing, not Oruka Therapeutics’ filing.
- Track GENETIC-AF enrollment, the impact of protocol amendments, DSMB timing and any decision on Phase 3.
- Assess cash burn against the stated end-of-2017 runway and the need and terms for additional financing or a strategic transaction.
- Review potential dilution from outstanding warrants, equity awards and any further securities issuance.
- Monitor Nasdaq listing compliance, companion diagnostic requirements, and the regulatory and clinical risks to Gencaro.